The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Roche’s Elecsys GDF-15 assay as a companion diagnostic (CDx) in cancer treatment.
The in vitro diagnostic immunoassay is designed for measuring Growth Differentiation Factor-15 (GDF-15) in cachectic adult patients with solid tumours for treatment with Pfizer’s investigational drug PF-06946860.
Cachexia is a metabolic disorder and comorbidity that occurs with various chronic diseases such as cancer, heart failure, chronic obstructive pulmonary disease (COPD), and chronic kidney disease (CKD).
It manifests as marked involuntary body weight loss, muscle atrophy, and reduced appetite, advancing to functional impairment and high death risk.
Cachexia is a common complication of cancer, and affects more than half of cancer patients globally.
As elevated GDF-15 is linked to cachexia in cancer patients, successful cachexia treatment can potentially lead to better cancer treatment.
Roche Diagnostics CEO Thomas Schinecker said: “We are pleased to partner with Pfizer to address this unmet medical need in oncology through strong companion diagnostics.
“The FDA BDD grant for the Elecsys GDF-15 assay shows the importance of these strong partnerships.
Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use,
BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.
Stock image by @everythingposs from Depositphotos